Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | MAT2A | P31153 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | DRD5 | P21918 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517383 | 0.94 | CNR1 (0.37) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4518633 | 0.93 | CNR1 (0.36) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4511508 | 0.91 | DRD1 (0.36) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4506682 | 0.90 | DRD1 (0.37) | DRD1DRD5PDE10ALMNATSHR | |
| SCHEMBL4510607 | 0.89 | DRD1 (0.36) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4288347 | 0.85 | DRD1 (0.39) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4977073 | 0.85 | DRD1 (0.39) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4515713 | 0.85 | DRD1 (0.39) | CNR1MAT2ADRD1DRD5PDE10A | |
| SCHEMBL4979252 | 0.84 | CNR1 (0.35) | CNR1MAT2ADRD1DRD5LMNA | |
| SCHEMBL4515222 | 0.83 | HKDC1 (0.41) | PDE10ALMNATSHRMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | BROWN REBECCA ELIZABETH | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298856-A1 | 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) | TRPV1, TRPV2, TRPV4 | CNR1 18/4885MAT2A 3846/4885DRD1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.